-
Product Insights
Net Present Value Model: Rebisufligene etisparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Rebisufligene etisparvovec Drug Details Rebisufligene etisparvovec...
-
Product Insights
Net Present Value Model: Prademagene zamikeracel
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Prademagene zamikeracel Drug Details Prademagene zamikeracel...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – prademagene zamikeracel
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry prademagene zamikeracel Drug Details Prademagene zamikeracel (EB-101) is under development for the treatment of...
-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa – Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the...
-
Product Insights
Batten Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as neuronal ceroid lipofuscinoses. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone, and movement problems. The Batten Disease Drugs in Development market research report provides an overview of the Batten Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Batten Disease, complete with analysis...
-
Product Insights
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
N-Sulphoglucosamine Sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III. The N-Sulphoglucosamine Sulphohydrolase - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for N-Sulphoglucosamine Sulphohydrolase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Product Insights
Epidermolysis Bullosa Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Epidermolysis Bullosa Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Epidermolysis Bullosa Clinical trials scenario. This report provides top line data relating to the clinical trials on Epidermolysis Bullosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Sector Analysis
United States Wound Care Management Market Outlook to 2025 – Advanced Wound Management, Compression Therapy, Negative Pressure Wound Therapy (NPWT) and Others
GlobalData’s “United States Wound Care Management Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Wound Care Management market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Advanced Wound Management, Compression Therapy, Negative Pressure Wound Therapy (NPWT), Ostomy Drainage Bags, Oxygen Therapy Devices, Pressure Relief Devices, Surgical Sutures, Tissue Engineered - Skin Substitutes, Traditional Wound Management, Wound Closure Devices and Wound Debridement Devices. The...